sermorelin for anti aging: Frequently asked questions

Tachyphylaxis (receptor desensitization) can occur if sermorelin is dosed daily without breaks or if it's combined with continuous GHRP use. The pituitary's GHRH receptors downregulate under constant stimulation. Implement a cycling protocol: five days on, two days off each week. This preserves receptor sensitivity long-term. Alternatively, rotate sermorelin with MK-677 (an oral ghrelin mimetic) every 8–12 weeks to prevent single-receptor fatigue.

Check thyroid function (TSH, free T3) and fasting insulin first. If TSH is above 3.0 or fasting insulin exceeds 10 μIU/mL, the pituitary's response to GHRH is blunted. Optimize those systems before increasing sermorelin dose. If thyroid and insulin are normal, the issue is likely pituitary reserve. Consider adding a GHRP like ipamorelin (100–200 mcg) to the evening dose. This works through a different receptor and can restore responsiveness. If combination therapy still fails, an insulin tolerance test or glucagon stimulation test can confirm whether the pituitary retains baseline somatotroph function.

This is common and generally safe. Testosterone and GH have synergistic anabolic effects on muscle protein synthesis and fat oxidation. However, both hormones are insulin antagonists. Monitor fasting glucose and HbA1c every 12 weeks during concurrent therapy. If fasting glucose rises above 100 mg/dL, add metformin (500–1,000 mg daily) or a GLP-1 agonist to preserve insulin sensitivity. The combination works best when the patient maintains a caloric deficit and resistance training protocol. Without those inputs, elevated GH and testosterone increase lean mass minimally.

These are signs of excessive GH elevation. Not a direct sermorelin effect but a consequence of overstimulation. Reduce the dose by 100 mcg and monitor symptoms for two weeks. If symptoms persist at the lower dose, discontinue sermorelin temporarily and measure IGF-1. If it's above 400 ng/mL, the patient is either hyperresponsive or has concurrent factors (like insulin resistance) amplifying GH's metabolic effects. Address insulin sensitivity before resuming.

Use an insulin cooler (FRIO wallet or similar) that maintains 2–8°C without ice or electricity for up to 48 hours. For longer trips, reconstitute peptides immediately before departure and keep the cooler pack refreshed. Unreconstituted lyophilised sermorelin tolerates ambient temperature (up to 25°C) for 72 hours but must be refrigerated upon arrival.

Discard the vial. Peptides in solution denature rapidly above 8°C. Even if the liquid appears clear, bioactivity degrades within 4–6 hours at room temperature. There is no reliable home test for peptide potency; continuing use wastes money on inactive compound. Temperature-logging during storage is the only preventive measure.

Confirm dosing accuracy and injection timing first. Non-response occurs in 10–15% of patients, typically due to severe pituitary atrophy or pre-existing GH receptor mutations. Consider adding a GHRP like ipamorelin (100–200mcg twice daily) to provide ghrelin-mediated stimulation alongside GHRH. If combined therapy fails to raise IGF-1 by week 12, pituitary imaging may be warranted.

Rotate injection sites across abdomen, thighs, and deltoids to prevent localised inflammation. Persistent reactions suggest bacteriostatic water sensitivity (benzyl alcohol allergy). Switch to sterile water and use the vial within 72 hours. Do not inject into areas with active skin conditions or recent trauma.

Growth hormone-releasing peptides (GHRPs) like GHRP-6 and ipamorelin work through a different receptor (the ghrelin receptor) and synergize with GHRH analogs like sermorelin. The combination produces greater GH release than either compound alone. A phenomenon documented in multiple trials. CJC1295 Ipamorelin 5MG 5MG is one such combination used in research protocols exploring this synergy.

This is the most common pattern reported in extended-use case series. Initial IGF-1 increases plateau or decline slightly after 12–16 weeks. The likely mechanism: pituitary somatotroph cells have a finite GH reserve that sermorelin depletes faster than the cells can replenish it, especially in older adults whose somatotroph density has already declined. Cycling protocols (4 weeks on, 2 weeks off) may allow pituitary recovery, but no controlled trials have tested this.

Non-response occurs in approximately 15–20% of subjects in published trials. The most common cause is severe pituitary atrophy. If somatotroph cell density is too low, GHRH receptor stimulation produces minimal GH release. Testing baseline GH response to a GHRH stimulation test can identify non-responders before starting a sermorelin protocol. Age, insulin resistance, and elevated cortisol all reduce GH responsiveness to GHRH.